ImpediMed (IPD) Q3 2026 earnings summary

Executive summary

• Q3 FY26 revenue reached $3.5 million, with annual recurring revenue (ARR) at $14.1 million ($14.9 million constant currency).

• SOZO Core Business TCV signed during the quarter was $5.4 million, up from $4.1 million in Q2 FY26.

• Cash receipts totaled $3.3 million, with a cash balance of $12.7 million at quarter end.

• Commercial activities in Heart Health and Weight Management began in the US, with initial sales in both markets.

• Appointment of new CEO, Erik Anderson, effective 7 April 2026, to accelerate US market engagement and drive toward cash flow break-even.

Financial highlights

• Quarterly revenue of $3.5 million, down 10% from Q2 FY26 due to prior distributor restocking and FX impact; US revenue up 2% constant currency.

• Net operating cash outflows were $4.5 million, mainly from staff costs ($4.5 million, down $0.8 million from Q2 FY26).

• Cash and cash equivalents at quarter end were $12.7 million, representing 2.9 quarters of funding.

• 36 SOZO units sold in Q3 FY26 (30 in US, 6 in ROW), compared to 57 in Q2 FY26.

• Unrealised FX loss of $0.7 million due to a stronger Australian dollar.

Outlook and guidance

• Positioned to capitalize on opportunities in BCRL, Heart Health, and Weight Management, leveraging FDA clearances and digital health platform.

• Expanding reimbursement coverage and clinical guidelines support expected to drive further commercialisation.

• New CEO aims to accelerate revenue growth, strengthen US health system engagement, and control costs.